Ketamine for Older Adults Pilot

Status Completed

Clinical Trial Summary

This pilot study will assess the safety and feasibility of intravenous (IV) ketamine in older adults with Treatment-Resistant Depression (TRD). In addition, this study will develop and utilize innovative methodological approaches to demonstrate the feasibility of precision medicine and mobile health approaches in depression treatment.

Clinical Trial Description

Participants in this study will receive ketamine infusions twice a week for 4 weeks (acute phase). Participants who respond or remit will continue with an additional 4 weeks of weekly ketamine infusions (continuation phase). Participants will be assessed at baseline, end of acute phase, and end of continuation phase for effectiveness, safety, and executive functioning. Participants will be asked to complete daily surveys of their depression symptoms during their participation. ;

Study Design

Related Conditions & MeSH terms

Depression
Depressive Disorder
Depressive Disorder, Treatment-Resistant
Geriatric Depression
Late Life Depression
Refractory Depression
Therapy-Resistant Depression
Treatment Resistant Depression

Clinical Trial Details

NCT number	NCT04504175
Study type	Interventional
Source	Washington University School of Medicine
Contact
Status	Completed
Phase	Phase 4
Start date	October 22, 2020
Completion date	March 15, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04124341` - PCS in Severe Treatment Resistant Depression	N/A
Recruiting	`NCT03887715` - A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression	N/A
Completed	`NCT04727229` - Stellate Ganglion Block for Major Depressive Disorder.	Phase 4
Completed	`NCT04634669` - Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)	Phase 2
Withdrawn	`NCT03175887` - Investigational TMS Treatment for Depression	N/A
Completed	`NCT03134066` - Neurocognitive Features of Patients With Treatment-Resistant Depression
Active, not recruiting	`NCT01984710` - Deep Brain Stimulation for Treatment Resistant Depression With the Medtronic Activa PC+S	N/A
Completed	`NCT01935115` - Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy	Phase 4
Terminated	`NCT01687478` - A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression	Phase 3
Completed	`NCT00531726` - Berlin Deep Brain Stimulation Depression Study	N/A
Recruiting	`NCT04041479` - Biomarker-guided rTMS for Treatment Resistant Depression	Phase 3
Recruiting	`NCT05870540` - BPL-003 Efficacy and Safety in Treatment Resistant Depression	Phase 2
Recruiting	`NCT04959253` - Psilocybin in Depression Resistant to Standard Treatments	Phase 2
Completed	`NCT04856124` - Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine
Recruiting	`NCT03272698` - ECT With Ketamine Anesthesia vs High Intensity Ketamine With ECT Rescue for Treatment-Resistant Depression	Phase 4
Active, not recruiting	`NCT04451135` - CET- REM (Correlating ECT Response to EEG Markers)	N/A
Recruiting	`NCT05680220` - 40 Hz Light Neurostimulation for Patients With Depression (FELIX)	N/A
Completed	`NCT03288675` - Stepped Care aiTBS 2 Depression Study (Ghent)	N/A
Recruiting	`NCT06138691` - KET-RO Plus RO DBT for Treatment Resistant Depression	Phase 1
Terminated	`NCT02675556` - Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression	Phase 1